Efficacy and Safety of Lenalidomide for Treatment of Low-/Intermediate-1-Risk Myelodysplastic Syndromes with or without 5q Deletion: A Systematic Review and Meta-Analysis
Fig 4
Forest plot of the odds ratio for achievement of RBC-TI in patients with low-risk vs intermediate-1-risk.